4.6 Article

Association of cancer history with Alzheimer's disease onset and structural brain changes

期刊

FRONTIERS IN PHYSIOLOGY
卷 5, 期 -, 页码 -

出版社

FRONTIERS MEDIA SA
DOI: 10.3389/fphys.2014.00423

关键词

cancer; Alzheimer's disease; inverse association; MRI; gray matter; APOE; genetics; ADNI

资金

  1. NIA [R01 AG19771, P30 AG10133]
  2. NLM [R01 LM011360]
  3. National Cancer Institute of the National Institutes of Health [R25CA117865]
  4. Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health) [U01 AG024904]
  5. DOD ADNI (Department of Defense) [W91XWH-12-2-0012]
  6. National Institute on Aging
  7. National Institute of Biomedical Imaging and Bioengineering
  8. Canadian Institutes of Health Research
  9. Northern California Institute for Research and Education
  10. Alzheimer's Association
  11. Alzheimer's Drug Discovery Foundation
  12. BioClinica, Inc.
  13. Biogen Idec Inc.
  14. Bristol-Myers Squibb Company
  15. Eisai Inc.
  16. Elan Pharmaceuticals, Inc.
  17. Eli Lilly and Company
  18. F. Hoffmann-La Roche Ltd. and its affiliated company Genetech, Inc.
  19. GE Healthcare
  20. Innogenetics, N.V.
  21. IXICO Ltd
  22. Janssen Alzheimer Immunotherapy Research & Development, LLC
  23. Johnson & Johnson Pharmaceutical Research & Development LLC
  24. Medpace, Inc.
  25. Merck Co., Inc.
  26. Meso Scale Diagnostics, LLC
  27. NeuroRx Research
  28. Novartis Pharmaceuticals Corporations
  29. Pfizer Inc.
  30. Piramal Imaging
  31. Servier
  32. Synarc Inc.
  33. Takeda Pharmaceutical Company

向作者/读者索取更多资源

Epidemiological studies show a reciprocal inverse association between cancer and Alzheimer's disease (AD). The common mechanistic theory for this effect posits that cells have an innate tendency toward apoptotic or survival pathways, translating to increased risk for either neurodegeneration or cancer. However, it has been shown that cancer patients experience cognitive dysfunction pre- and post-treatment as well as alterations in cerebral gray matter density (GMD) on MRI. To further investigate these issues, we analyzed the association between cancer history (CA+/-) and age of AD onset, and the relationship between GMD and CA+/- status across diagnostic groups in the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort study. Data was analyzed from 1609 participants with information on baseline cancer history and AD diagnosis, age of AD onset, and baseline MRI scans. Participants were CA+/- (N = 503) and CA- (N = 1106) diagnosed with AD, mild cognitive impairment (MCI), significant memory concerns (SMC), and cognitively normal older adults. As in previous studies, CA+ was inversely associated with AD at baseline (P = 0.025); interestingly, this effect appears to be driven by non-melanoma skin cancer (NMSC), the largest cancer category in this study (P = 0.001). CA+ was also associated with later age of AD onset (P < 0.001), independent of apolipoprotein E (APOE) epsilon 4 allele status, and individuals with two prior cancers had later mean age of AD onset than those with one or no prior cancer (P < 0.001), suggesting an additive effect. Voxel-based morphometric analysis of GMD showed CA+ had lower GMD in the right superior frontal gyrus compared to CA across diagnostic groups (P-crit < 0.001, uncorrected); this cluster of lower GMD appeared to be driven by history of invasive cancer types, rather than skin cancer. Thus, while cancer history is associated with a measurable delay in AD onset independent of APOE epsilon 4, the underlying mechanism does not appear to be cancer-related preservation of GMD.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据